IND Application for SinoMab’s First-in-Class Asthma Therapeutic Product SM17 Accepted by FDA
HONG KONG, Feb 17, 2022 – […]
中国抗体用于哮喘的第一类治疗产品SM17新药研究申请获FDA受理
HONG KONG, Feb 16, 2022 – […]...
sm17
HONG KONG, Feb 17, 2022 – […]
HONG KONG, Feb 16, 2022 – […]...